ATE157397T1 - Lebende vakzine - Google Patents

Lebende vakzine

Info

Publication number
ATE157397T1
ATE157397T1 AT91906493T AT91906493T ATE157397T1 AT E157397 T1 ATE157397 T1 AT E157397T1 AT 91906493 T AT91906493 T AT 91906493T AT 91906493 T AT91906493 T AT 91906493T AT E157397 T1 ATE157397 T1 AT E157397T1
Authority
AT
Austria
Prior art keywords
microorganism
live vaccines
dna encoding
immunoprophylaxis
mutation
Prior art date
Application number
AT91906493T
Other languages
German (de)
English (en)
Inventor
Gordon Dougan
Ian George Charles
Carlos Hormaeche
Kevin Stuart Johnson
Steven Neville Chatfield
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Application granted granted Critical
Publication of ATE157397T1 publication Critical patent/ATE157397T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/826—Bacterial vaccine for avian species, e.g. poultry or other birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT91906493T 1990-03-30 1991-03-28 Lebende vakzine ATE157397T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909007194A GB9007194D0 (en) 1990-03-30 1990-03-30 Live vaccines

Publications (1)

Publication Number Publication Date
ATE157397T1 true ATE157397T1 (de) 1997-09-15

Family

ID=10673583

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91906493T ATE157397T1 (de) 1990-03-30 1991-03-28 Lebende vakzine

Country Status (19)

Country Link
US (2) US5804194A (enExample)
EP (1) EP0524205B1 (enExample)
JP (1) JP3054440B2 (enExample)
KR (1) KR100202771B1 (enExample)
AT (1) ATE157397T1 (enExample)
CA (1) CA2079463C (enExample)
DE (1) DE69127440T2 (enExample)
DK (1) DK0524205T3 (enExample)
ES (1) ES2106776T3 (enExample)
GB (1) GB9007194D0 (enExample)
GR (1) GR3025258T3 (enExample)
HU (1) HU217776B (enExample)
IE (1) IE911037A1 (enExample)
IL (1) IL97720A (enExample)
MY (1) MY130001A (enExample)
NZ (1) NZ237616A (enExample)
TW (1) TW205567B (enExample)
WO (1) WO1991015572A1 (enExample)
ZA (1) ZA912397B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662908A (en) * 1985-07-31 1997-09-02 The Board Of Trustees Of The Leland Stanford Jr. University Invasive microorganisms
DE69229221T2 (de) * 1991-03-05 1999-09-23 The Wellcome Foundation Ltd., Greenford Expression rekombinanter proteine in attenuierten bakterien
AU675940B2 (en) * 1992-03-02 1997-02-27 Board Of Trustees Of The Leland Stanford Junior University Microorganisms having attenuated invasiveness
EP0659086B1 (en) * 1992-09-04 1998-11-11 The University of Saskatchewan Novel bacterial vaccines using vaccine strains of pathogenic bacteria
JPH08510756A (ja) 1993-06-04 1996-11-12 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ ストレス蛋白質とその使用
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
GB9401795D0 (en) * 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccines
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5985270A (en) * 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5796671A (en) 1996-03-01 1998-08-18 Wahlstrom; Sven E. Dynamic random access memory
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
US5830464A (en) 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
IL134341A0 (en) 1997-08-05 2001-04-30 Stressgen Biotechnologies Corp Compositions for inducing an immune response containing an hpv protein antigen
US6905691B1 (en) 1997-12-11 2005-06-14 Celltech Pharma Europe Limited Vaccines containing attenuated bacteria
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
CU22661A1 (es) * 1997-12-30 2001-04-27 Cnic Ct Nac Investigaciones Nuevos candidatos vacunales de vibrio cholerae y método de obtención
ES2355483T3 (es) 1998-02-20 2011-03-28 University Of Miami Complejo de proteina de choque térmico modificada-péptido antigénico.
GB9806449D0 (en) * 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
NZ511449A (en) * 1998-12-02 2004-05-28 Univ Maryland Plasmid maintenance system for antigen delivery
US6413768B1 (en) 1998-12-02 2002-07-02 University Of Maryland Expression plasmids
US8076130B2 (en) 1998-12-02 2011-12-13 University Of Maryland, Baltimore Plasmid maintenance system for antigen delivery
US6497880B1 (en) 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
FR2787810B1 (fr) * 1998-12-24 2002-10-31 Inst Nat De La Rech Agronomique Inra Bacteries a gram positif depourvues d'activite proteasique htra, et leurs utilisations
WO2001004344A2 (en) 1999-07-08 2001-01-18 Stressgen Biotechnologies Corporation Induction of a th1-like response in vitro
WO2001051081A1 (en) 2000-01-14 2001-07-19 Whitehead Institute For Biomedical Research In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent
HK1052301A1 (zh) 2000-06-02 2003-09-11 University Of Connecticut Health Center α(2)巨球蛋白与抗原分子的复合物作免疫治疗用途
NZ523408A (en) 2000-06-26 2006-02-24 Stressgen Biotechnologies Corp Human papilloma virus treatment
US6872547B1 (en) 2000-10-11 2005-03-29 Washington University Functional balanced-lethal host-vector systems
KR20030074787A (ko) 2001-02-05 2003-09-19 스트레스젠 바이오테크놀러지스 코포레이션 Ｂ형 간염 바이러스 치료
ITRM20010295A1 (it) * 2001-05-30 2002-12-02 Stresstech S R L Metodo per ottenere microrganismi patogeni non virulenti attraverso una modificazione dello stato fisico e/o dinamico delle loro membrane bi
CN1635896A (zh) 2001-08-20 2005-07-06 康涅狄格大学健康中心 包含用于治疗癌症及感染性疾病的热休克蛋白或α2－巨球蛋白的组合物制备方法
GB0121998D0 (en) 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
US7541043B2 (en) 2002-01-16 2009-06-02 The United States Of America As Represented By The Department Of Health And Human Services Vaccine for protection against Shigella sonnei disease
UA100370C2 (uk) 2006-12-11 2012-12-25 Мериал Лимитед Спосіб вакцинації птахів проти salmonella
EP2257301B1 (en) 2008-03-03 2014-01-22 The University of Miami Allogeneic cancer cell-based immunotherapy
CA2718884C (en) 2008-03-20 2016-11-22 University Of Miami Heat shock protein gp96 vaccination and methods of using same
IL214246B (en) * 2011-07-21 2018-08-30 Shafferman Avigdor Vaccines produced from htra-defective Bacillus anthraxis
CA2945052C (en) 2014-04-15 2023-05-02 Griffith University Group a streptococcus vaccine
KR20170109582A (ko) 2015-02-06 2017-09-29 히트 바이오로직스, 인코퍼레이티드 벡터 공동 발현 백신 및 공동 자극 분자
CA3040123A1 (en) 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
CA3058938A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
JP2023503963A (ja) 2019-11-25 2023-02-01 グリフィス ユニバーシティー 淋菌感染症に対する免疫原性タンパク質

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4337314A (en) * 1979-05-23 1982-06-29 Research Corporation Genetically attenuated bacterial vaccines with multiple mutations of the same phenotype
US4735801A (en) * 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
GB8314645D0 (en) * 1983-05-26 1983-06-29 Wellcome Found Bivalent vaccines
EP0300035B1 (en) * 1987-01-30 1995-05-10 The President And Fellows Of Harvard College Periplasmic protease mutants of escherichia coli
US4895717A (en) * 1987-07-10 1990-01-23 The United States Of America As Represented By The Secretary Of Agriculture Revertant serotype 1 Marek's disease vaccine
GB8730037D0 (en) * 1987-12-23 1988-02-03 Wellcome Found Vaccines
US5114844A (en) * 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
GB8912330D0 (en) * 1989-05-30 1989-07-12 Wellcome Found Live vaccines

Also Published As

Publication number Publication date
WO1991015572A1 (en) 1991-10-17
TW205567B (enExample) 1993-05-11
IL97720A (en) 1999-06-20
IE911037A1 (en) 1991-10-09
IL97720A0 (en) 1992-06-21
ES2106776T3 (es) 1997-11-16
NZ237616A (en) 1994-03-25
DK0524205T3 (da) 1997-10-27
US5980907A (en) 1999-11-09
JPH05507842A (ja) 1993-11-11
DE69127440D1 (de) 1997-10-02
HU217776B (hu) 2000-04-28
HUT65496A (en) 1994-06-28
KR100202771B1 (ko) 1999-06-15
JP3054440B2 (ja) 2000-06-19
AU659995B2 (en) 1995-06-08
MY130001A (en) 2007-05-31
CA2079463A1 (en) 1991-10-01
EP0524205A1 (en) 1993-01-27
HU9203098D0 (en) 1992-12-28
AU7541791A (en) 1991-10-30
CA2079463C (en) 2002-03-05
US5804194A (en) 1998-09-08
DE69127440T2 (de) 1998-01-02
GR3025258T3 (en) 1998-02-27
ZA912397B (en) 1992-11-25
GB9007194D0 (en) 1990-05-30
EP0524205B1 (en) 1997-08-27

Similar Documents

Publication Publication Date Title
DK0524205T3 (da) Levende vacciner
DK0574466T3 (da) Udtrykkelse af rekombinante proteiner i svækkede bakterier
ATE359370T1 (de) Heterologe antigene in stämmen zur impfung mit lebendzellen
ATE454163T1 (de) Bakterielle impfstoffe, enthaltend auxotrophe attenuierte listerienstämme, welche heterologe antigene exprimieren
ATE47524T1 (de) Hundeparvovirus-impfstoffe.
ATE90388T1 (de) Schuetzendes peptid-antigen.
MY105080A (en) Heat-labile toxin b subunit fusion proteins.
DK0625157T3 (da) Blodplade-GPIIIaP1A1- og -P1A2-epitoper og fremstilling og anvendelse deraf
ATE242784T1 (de) Mit der familie der hämolysin-toxine verwandte antigene eisen-ubnterdrückende proteine des n. meningitis
DE68916424D1 (de) Pasteurella-impfstoff.
EP0652769A1 (en) Vaccines against Metazoon parasites.
AU1853995A (en) Vaccine compositions
ATE166880T1 (de) Impfstoff gegen cholera
DK230890A (da) Dna-fragment, der koder for et pasteurella multocida-toxin eller for en subsekvens eller analog deraf, ekspressionsvektor, der omfatter dna-fragmentet, mikroorganisme, der udtrykker dette, fremgangsmaade til fremstilling af et pasteurella-multocida-toxin, diagnostisk middel samt anvendelse heraf, vaccine indeholdende et pasteurella-multocida-toxinderivat, anvendelse af pasteurella multocida-t m.m.
DK0742829T3 (da) Ekspression af heterologe proteiner i svækkede bakterier under anvendelse af HTRA-promotorerne

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time